Ethical issues and risk/benefit assessment of iron chelation therapy: Advances with deferiprone/deferoxamine combinations and concerns about the safety, efficacy and costs of deferasirox [Kontoghiorghes GJ, Hemoglobin 2008; 32(1-2):1-15.]

Hemoglobin

Volumn 32, Issue 6, 2008, Pages 601-607

  Porter, John B ^a,e   Taher, Ali T ^b   Cappellini, Maria D ^c   Vichinsky, Elliott P ^d  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b AMERICAN UNIVERSITY OF BEIRUT   (Lebanon)

^c UNIVERSITY OF MILAN   (Italy)

^d CHILDREN S HOSPITAL OAKLAND   (United States)

^e UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DEFERASIROX; DEFERIPRONE; DEFEROXAMINE;

AGRANULOCYTOSIS; ARTHROPATHY; BETA THALASSEMIA; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; CYTOPENIA; DIARRHEA; DRUG EFFICACY; DRUG ERUPTION; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ETHICS; EYE TOXICITY; HUMAN; IRON CHELATION; KIDNEY FAILURE; LETTER; LIVER TOXICITY; MYELODYSPLASTIC SYNDROME; NAUSEA; NEUTROPENIA; OTOTOXICITY; RISK BENEFIT ANALYSIS; SICKLE CELL ANEMIA; THROMBOCYTOPENIA; VOMITING;

BENZOIC ACIDS; CHELATION THERAPY; DEFEROXAMINE; DRUG COSTS; DRUG TOXICITY; HEMATOLOGIC DISEASES; HUMANS; IRON CHELATING AGENTS; PYRIDONES; RISK ASSESSMENT; SIDEROPHORES; TRIAZOLES;

EID: 57649112004     PISSN: 03630269     EISSN: 1532432X     Source Type: Journal    
DOI: 10.1080/03630260802342008     Document Type: Letter

References (23)

1. Kontoghiorghes GJ. Ethical issues and risk/benefit assessment of iron chelation therapy: Advances with deferiprone/deferoxamine combinations and concerns about the safety, efficacy and costs of deferasirox. Hemoglobin 2008; 32(1-2):1-15.
2. Porter J, Galanello R, Saglio G, Neufeld EJ, Vichinsky E, Cappellini MD, Olivieri N, Piga A, Cunningham MJ, Soulieres D, Gattermann N, Tchernia G, Maertens J, Giardina P, Kwaitkowski J, Quarta G, Jeng M, Forni GL, Stadler M, Cario H, Debusscher L, Della Porta M, Cazzola M, Greensberg P, Alimena G, Rabault B, Gathmann I, Ford JM, Alberti D, Rose C. Relative response of patients with myelodysplastic syndromes and other transfusion-dependent anaemias to deferasirox (ICL670): A 1-yr prospective study. Eur J Haematol 2008; 80(2):168-176.
3. Galanello R, Piga A, Forni GL, Bertrand Y, Foschini ML, Bordone E, Leoni G, Lavagetto A, Zappu A, Longo F, Maseruka H, Hewson N, Sechaud R, Belleli R, Alberti D. Randomized phase II trial of deferasirox (Exjade, ICL670), a once-daily oral chelating agent, in paediatric patients with β-thalassaemia major. Haematologica 2006; 91(10):1343-1351.
4. Piga A, Galanello R, Forni GL, Cappellini MD, Origa R, Zappu A, Donato G, Bordone E, Lavagetto A, Zanaboni L, Sechaud R, Hewson N, Ford JM, Opitz H, Alberti D. Randomized phase II trial of deferasirox (Exjade, ICL670), a once-daily, orally-administered iron chelator, in comparison to deferoxamine in thalassemia patients with transfusional iron overload. Haematologica 2006;91(7):873-880.
5. Cappellini MD, Cohen A, Piga A, Bejaoui M, Perrotta S, Agaoglu L, Aydinok Y, Kattamis A, Kilinc Y, Porter J, Capra M, Galanello R, Fattoum S, Drelichman G, Magnano C, Verissimo M, Athanassiou-Metaxa M, Giardina P, Kourakli-Symeonidis A, Janak-Scahub G, Coates T, Vermylen C, Olivieri N, Thuret I, Opitz H, Ressayre-Djaffer C, Marks P, Alberti D. A phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with β-thalassemia. Blood 2006; 107(9):3455-3462.
6. Vichinsky E, Onyekwere O, Porter J, Swerdlow P, Eckman J, Lane P, Files B, Hassell K, Kelly P, Wilson F, Bernaudin F, Forni GL, Okpala I, Ressyer-Djaffer C, Alberti D, Holland J, Marks P, Fung E, Fischer R, Mueller BU, Coates T. A randomized comparison of deferasirox versus deferoxamine for the treatment of transfusional iron overload in sickle cell disease. Br J Haematol 2007;136(3):501-508.
7. Cappellini MD, Vichinsky E, Galanello R, Piga A, Williamson P, Porter JB. Long-term treatment with deferasirox (Exjade®, ICL670), a once-daily oral iron chelator, is effective in patients with transfusion-dependent anemias. (Abstract 2777) Blood 2007; 110(11):816b.
8. Cohen AR, Galanello R, Piga A, De Sanctis V, Tricta F. Safety and effectiveness of long-term therapy with the oral iron chelator deferiprone. Blood 2003; 102(5):1583-1587.
9. Brissot P, Deugnier Y, Cianciulli P, Cario H, Jeng M, Rabault B. Correlation between dose-dependent reductions in serum transaminase (ALT) and serum ferritin levels during long-term chelation therapy with deferasirox (Exjade®, ICL670). (Abstract 3817) Blood 2006; 108(11):30b.
10. Exjade (deferasirox) Prescribing Information. Novartis Pharmaceuticals Corporation. http://www.exjade.com 2007.
11. Delea TE, Sofrygin O, Thomas SK, Baladi JF, Phatak PD, Coates TD. Cost effectiveness of once-daily oral chelation therapy with deferasirox versus infusional deferoxamine in transfusion-dependent thalassaemia patients. US healthcare system perspective. Pharmacoeconomics 2007;25(4):329-342.
12. Ubel PA, Hirth RA, Chernew ME, Fendrick AM. What is the price of life and why doesn't it increase at the rate of inflation? Arch Intern Med 2003; 163(14):1637-1641.
13. Hirth RA, Chernew ME, Miller E, Fendrick AM, Weissert WG. Willingness to pay for a quality-adjusted life year: In search of a standard. Med Decis Making 2000; 20(3):332-342.
14. Lucas GN, Perera BJ, Fonseka EA, De Silva DD, Fernadopulle M, Karunatilaka DH, Weerasinghe I. Experience with the oral iron chelator deferiprone in transfusion-dependent children. Ceylon Med J 2002; 47(4):119-121.
15. Nick H, Wong A, Acklin P, Faller B, Jin Y, Lattmann R, Sergejew T, Hauffe S, Thomas H, Schnebli HP. ICL670A: preclinical profile. Adv Exp Med Biol 2002; 509:185-203.
16. Cohen AR, Glimm E, Porter JB. Effect of transfusional iron intake on response to chelation therapy in β-thalassemia major. Blood 2008; 111(2):583-587.
17. Glickstein H, Ben El R, Shvartsman M, Cabantchik ZI. Intracellular labile iron pools as direct targets of iron chelators. A fluorescence study of chelator action in living cells. Blood 2005;106(9):3242-3250.
18. Wood JC, Otto-Duessel M, Gonzales I, Gonzalez I, Aguilar MI, Shimada H, Nick H, Nelson M, Moats R. Deferasirox and deferiprone remove cardiac iron in the iron-overloaded gerbil. Translational Res 2006; 148(5):272-280.
19. Porter JB, Tanner MA, Pennell DJ, Eleftheriou P. Improved myocardial T2* in transfusion dependent anemias receiving ICL670 (deferasirox). (Abstract 3600) Blood 2005; 106(11):1003a.
20. Taher A, El-Beshlawy A, Al Jefri A, Elalfy M, Al Zir K, Daar S, Damanbouri G, Krahn U, Pfluger D, Hadler D. Treatment with the once-daily, oral iron chelator deferasirox is effective and well tolerated in β-thalassaemia patients with a high iron burden. (Abstract 808) Haematologica 2007;92(Suppl 1):302.
21. Wood JC, Otto-Duessel M, Aguilar M, Nick HP, Coates TC, Rex M. Dose response of deferoxamine, deferiprone, and ICL670 chelation therapy in a gerbil model of iron overload. (Abstract 3621) Blood 2004; 104(11):985a.
22. Cappellini MD, Vichinsky E, Ford JM, Rabault B, Porter J. Evaluation of deferasirox (Exjade®, ICL670) therapy in patients with transfusional iron overload who achieve serum ferritin (SF) <=1000 ng/mL in long-term studies. (Abstract 3795) Blood 2007; 110(11; Suppl 2):16b.
23. Cappellini MD, Bejaoui M, Agaoglu L, Porter J, Coates T, Jeng M, Lai ME, Mangiagli A, Strauss G, Girot R, Watman N, Ferster A, Loggetto S, Abish S, Cario H, Zoumbos N, Vichinsky E, Opitz H, Ressayre-Djaffer C, Abetz L, Rofail D, Baladi JF. Prospective evaluation of patient-reported outcomes during treatment with deferasirox or deferoxamine for iron overload in patients with β-thalassemia. Clin Ther 2007; 29(5):909-917.